Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00133627
Status:
COMPLETED
Last Update Posted:
2011-11-17
First Post:
2005-08-22
Brief Title:
Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Safety and Efficacy Comparison Ketotifen Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis
Status:
COMPLETED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Medications available for the treatment of seasonal allergic conjunctivitis include antihistamines These medicines block the release of histamine a substance in the body that is released when an allergic reaction occurs Novartis NVS has developed an eye drop formulation of a well tried antihistamine called ketotifen This study will compare the efficacy and the tolerability of ketotifen eye drops with emedastine which is a popular treatment for seasonal allergic conjunctivitis in China
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None